v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 77,581 $ 70,495
Short-term marketable securities (amortized cost of $140,762 and $156,246, respectively) 140,753 156,485
Accounts receivable, net 48,315 50,365
Inventory 11,206 9,820
Prepaid expenses and other current assets 13,952 13,020
Total current assets 291,807 300,185
Long-term assets    
Property and equipment, net 30,774 34,107
Operating lease right-of-use assets 40,248 40,616
Long-term marketable securities (amortized cost of $18,908 and $13,220, respectively) 18,889 13,234
Restricted cash 2,709 2,689
Intangible assets, net 1,307 1,726
Goodwill 118,972 118,972
Other assets 1,237 1,207
Total assets 505,943 512,736
Current liabilities    
Accounts payable 9,615 6,467
Accrued liabilities 7,465 7,700
Accrued compensation and benefits 6,217 16,992
Current portion of operating lease liabilities 8,513 8,920
Current portion of deferred revenue 49,397 45,194
Current portion of revenue interest liability, net 5,804 4,642
Total current liabilities 87,011 89,915
Long-term liabilities    
Operating lease liabilities, less current portion 69,115 70,228
Deferred revenue, less current portion 807 1,006
Revenue interest liability, net, less current portion 124,749 126,566
Other long-term liabilities 20 20
Total liabilities 281,702 287,735
Commitments and contingencies (Note 9)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2026 and December 31, 2025; 159,697,221 and 153,779,418 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 16 15
Additional paid-in capital 1,599,708 1,581,848
Accumulated other comprehensive (loss) gain (28) 253
Accumulated deficit (1,383,356) (1,363,323)
Total Adaptive Biotechnologies Corporation shareholders’ equity 216,340 218,793
Noncontrolling interest 7,901 6,208
Total shareholders’ equity 224,241 225,001
Total liabilities and shareholders’ equity $ 505,943 $ 512,736